It seems Eisai and Biogen have another hurdle to jump over in their bid to get EU approval for their Alzheimer's disease therapy Leqembi. In the latest development, the European Commission has ...

Drug cost-effectiveness organisation ICER has revised its view of Eisai’s new Alzheimer’s disease therapy Leqembi, but has concluded that the price set by the pharma group is still too high.

which also include lecanemab (Leqembi). The donanemab secondary analysis "largely reinforces some of the key observations in the donanemab clinical trials -- that careful patient selection and ...

Numerous studies have hinted that women are particularly susceptible to tau pathology, but scientists have lacked definitive data. Now, a meta-analysis of six longitudinal tau PET studies offers the ...

Health care systems that adopted a higher volume of telehealth services less frequently used several low-value screening and diagnostic tests, according to results of a cohort study published in ...

Try these speed reading exercises to improve reading. You can also learn something about the news. There are reading texts at different levels. You can choose the reading speed of each text. If one ...